CMD-504

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCMD-504
Drug Alias NameCAR T-cell therapy (Cell Medica/Baylor College of Medicine)CAR NKT-cell therapy (Cell Medica/Baylor College of Medicine)anti-CSPG4 CAR NK-cell therapy (Baylor College of Medicine/Cell)CMD-504
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionChondroitin sulfate proteoglycan 4 modulators
TargetsChondroitin sulfate proteoglycan 4
Therapy Area/IndicationsBreast NeoplasmsGlioblastomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKuur Therapeutics LimitedBaylor College Of Medicine
Active IndicationsN/A
Inactive IndicationsBreast NeoplasmsGlioblastomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A